Mashiro Okunaka

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 4

Top Topics

Advanced Non Small Cell Lung Cancer

Tyrosine Kinase

Coronary Artery Bypass

Top Venues

Therapeutic advances in medical oncology

Integrative cancer therapies

This page only lists publications with an associated author ORCID identifier.

Publications

Mashiro Okunaka, Daisuke Kotani, Saori Mishima, Maho Nakamura, Akihito Kawazoe, Hideaki Bando, Takayuki Yoshino, Kohei Shitara
Potential Efficacy of Shiunko for Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody-Induced Skin Fissure: A Single Institutional Case Series. Integrative cancer therapies 23 (2024)
Mashiro Okunaka, Daisuke Kotani, Hisashi Fujiwara, Kazuma Sato, Naoto Fujiwara, Saori Mishima, Shingo Sakashita, Takayuki Yoshino, Takeo Fujita, Takashi Kojima
Prognosis of patients with residual pathological disease after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil therapy and surgery for esophageal squamous cell carcinoma: a retrospective cohort study. Therapeutic advances in medical oncology 16 (2024)
Mashiro Okunaka, Daisuke Kotani, Saori Mishima, Maho Nakamura, Akihito Kawazoe, Hideaki Bando, Takayuki Yoshino, Kohei Shitara
Potential Efficacy of Shiunko for Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody-Induced Skin Fissure: A Single Institutional Case Series. Integrative cancer therapies 23 (2024)
Mashiro Okunaka, Daisuke Kotani, Hisashi Fujiwara, Kazuma Sato, Naoto Fujiwara, Saori Mishima, Shingo Sakashita, Takayuki Yoshino, Takeo Fujita, Takashi Kojima
Prognosis of patients with residual pathological disease after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil therapy and surgery for esophageal squamous cell carcinoma: a retrospective cohort study. Therapeutic advances in medical oncology 16 (2024)